{"task_id": "72bce4a0c672af4a", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 247/464)", "text": "s\nPATHOPHYSIOLOGY (CONT\u2019D)\n236\nFebrile Neutropenia\n\n--- Page 258 ---\nCLINICAL FEATURES\nHISTORY\npatients\nusually\nasymptomatic\nother\nthan fever. Determine severity and duration of\nfever, associated signs and symptoms (cough, dys\npnea, chest pain, diarrhea, abdominal pain, dysuria,\nurethral discharge, neck stiffness, headache, rash),\nrecent chemotherapy (nadir of neutrophil counts\nusually 10 14 days post treatment), weight loss,\nnight sweats, travel history, sexual history, immuniza\ntions, past medical history (malignancy, rheumatolo\ngic disorders), medications (chemotherapy, GCSF)\nPHYSICAL\nvitals (tachycardia, tachypnea, hypoten\nsion, fever, hypoxemia), oral ulcers, lymphadenopathy,\nnuchal rigidity, respiratory and cardiac examination\n(murmurs), abdominal examination (hepatosplenome\ngaly), skin lesions (morphology, distribution). Important\nsites to examine include venous access devices, sinuses,\nand perianal region for abscess. Digital rectal examina\ntion is not recommended as potential rectal tear\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, lytes, urea, Cr, AST, ALT, ALP, bilir\nubin, urinalysis\n\u0002\nMICROBIOLOGY\nblood C&S\u00052 (culture periph\neral blood in addition to central line ports, spu\ntum Gram stain/AFB/C&S, urine C&S, stool C&S,\nO&P, C. difficile toxin (if diarrhea)\n\u0002\nIMAGING\nCXR\nSPECIAL\n\u0002\nSINUS X ray\nMANAGEMENT\nLOW RISK (ANC >0.1\u0005109/L, peak temperature\n<398C [102.28F], no significant symptoms or signs,\nno significant comorbidities, nearly normal renal and\nhepatic function, neutropenia <7 days)\nciprofloxa\ncin 500 mg PO BID + amoxicillin clavulanate 500 mg\nPO q8h. May send home with follow up\nHIGH RISK\nadmit for intravenous antibiotics\n\u0002\nFIRST LINE\none of imipenem 500 mg IV q6h, mer\nopenem 2 g IV q8h, ceftazidime 2 g IV q8h, cefepime\n2 g IV q8h, piperacillin/tazobactam 4.5 g IV q8h,\npiperacillin 3 g IV q4h plus tobramycin 2 2.5 mg/kg\nIV q8h, clindamycin 600 mg IV q8h plus tobramycin\n7 mg/kg IV q24h, or piperacillin/tazobactam 4.5 g\nIV q8h plus gentamicin 2 2.5 mg/kg IV q8h\n\u0002\nSECOND LINE\nadd vancomycin 1 g IV q12h if\nsuspect line infection, known colonization MRSA,\nGram positive blood culture, or hypotension\n\u0002\nTHIRD LINE\naddantifungaliffebrileafter5days(fluco\nnazole 400 mg IV daily, itraconazole 200 mg IV daily,\namphotericinB 0.5 1 mg/kg IVdailyover 4 h, caspofun\ngin 70 mg on first day followed by 50 mg IV daily)\nGCSF SUPPORT\nsee TREATMENT ISSUES below\nMANAGEMENT (CONT\u2019D)\nCATHETER REMOVAL\nnecessary for most patients\nwith bacteremia/candidemia with organisms other\nthan coagulase negative Staphylococci\nTREATMENT ISSUES\nMODIFICATION OF THERAPY DURING FIRST WEEK\nOF TREATMENT\n\u0002\nIF PATIENT BECOMES AFEBRILE IN 3\u20135 DAYS\n\u0002\nKNOWN ORGANISM\nswitch to specific antibiotics\n\u0002\nUNKNOWN ETIOLOGY AND LOW RISK\nswitch to\nciprofloxacin plus amoxicillin clavulanate after\nafebrile for 48 h\n\u0002\nUNKNOWN ETIOLOGY AND HIGH RISK\ncontinue\nsame antibiotics\n\u0002\nIF PERSISTENT FEVER DURING FIRST 3\u20135 DAYS\n\u0002\nCLINICALLY STABLE BY DAY 3\ncontinue antibio\ntics, stop vancomycin if cultures negative\n\u0002\nPROGRESSIVE\nDISEASE\nBY\nDAY\n3\nchange\nantibiotics\n\u0002\nFEBRILE AFTER DAY 5\nadd antifungal\nDURATION OF ANTIBIOTIC TREATMENT\n\u0002\nIF AFEBRILE BY DAY 3\n\u0002\nSTOP ANTIBIOTICS\nif (1) ANC \u00030.5\u0005109/L for 2\nconsecutive days, afebrile for \u000348 h, cultures\nnegative, and no obvious signs of infection, or if\n(2) ANC <0.5\u0005109/L by day 7, but afebrile for\n5 7 days, patient initially at low risk, and no\nsubsequent complications\n\u0002\nCONTINUE ANTIBIOTICS\nif above criteria not met\n\u0002\nIF PERSISTENT FEVER ON DAY 3\n\u0002\nSTOP ANTIBIOTICS\nif ANC \u00030.5\u0005109/L for 4 5\nconsecutive days\n\u0002\nCONTINUE\nANTIBIOTICS\nif\nANC\n<0.5\u0005109/L,\nreassess and continue antibiotics for 2 weeks.\nConsider stopping therapy if no disease site is\nfound and condition is stable\nPRE MEDICATIONS\nFOR\nAMPHOTERICIN\nB\nmeperidine 50 mg IV, acetaminophen 2 tabs PO,\nhydrocortisone 25 mg IV 30 min before dose, and\nrepeat \u00051 1 2 h after administration\nASCO 2006 GUIDELINE FOR GCSF USE\n\u0002\nPRIMARY PROPHYLAXIS\nGCSF is recommended for\nthe prevention of febrile neutropenia if\n\u0002\nHIGH-RISK PATIENTS\nbased on age (>65), med\nical history (poor performance status, previous\nfebrile neutropenia, extensive prior treatment,\npoor nutrition, open wounds, active infections),\ndisease characteristics (bone marrow involve\nment), and myelotoxicity of the chemotherapy\nregimen (chemoradiation)\n\u0002\nCHEMOTHERAPY REGIMENS\n20% or higher risk of\nfebrile neutropenia or dose dense regimens\n\u0002\nSECONDARY PROPHYLAXIS\nGCSF is recommended\nfor patients who experienced a neutropenic compli\ncation from a prior cycle of chemotherapy (in which\nFebrile Neutropenia\n237", "text_length": 4564, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 247/464)", "type": "chunk", "chunk_index": 246, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.587197", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.588202", "status": "complete", "chunks_added": 3}